• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OrbusNeich

Japan OKs OrbusNeich’s Combo Plus stent

September 25, 2019 By Danielle Kirsh

orbusneich-logo

OrbusNeich Medical today said it won market approval in Japan for its Combo Plus coronary stent. The Combo Plus stent is designed to address the risk of stent thrombosis associated with delayed healing in conventional drug-eluting stents. The Combo Plus DES uses endothelial progenitor cell capture technology and abluminal sirolimus drug elution delivered from a […]

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance, Stents Tagged With: OrbusNeich

ACC ’18 Roundup: OrbusNeich Combo drug-eluting stent succeeds in registries

March 12, 2018 By Sarah Faulkner

ACC '18

OrbusNeich touted pooled data from two registries evaluating its dual-therapy stent this week at the annual meeting of the American College of Cardiology. The Combo stent was implanted in more than 3,600 all-comer patients and followed by researchers for one year. The registries found that the device was safe and effective after one year, featuring a […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: OrbusNeich

TCT 2017: Medtronic & OrbusNeich evaluate shortening dual anti-platelet therapy with drug-eluting stents

November 2, 2017 By Sarah Faulkner

Medtronic

At this year’s Transcatheter Cardiovascular Therapeutics meeting, companies presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients treated with a drug-eluting stent. Among those companies were Medtronic (NYSE:MDT) and OrbusNeich. Here’s a look at what they found. Medtronic’s DAPT-STEMI trial Yesterday, investigators presented data from Medtronic’s independently-run DAPT-STEMI trial, […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Medtronic, OrbusNeich

TCT 2017: OrbusNeich’s dual therapy stent non-inferior to Abbott’s Xience DES in 1-year follow-up

October 31, 2017 By Sarah Faulkner

OrbusNeich

OrbusNeich touted results today from a pivotal registration study comparing its Combo dual therapy stent with Abbott‘s (NYSE:ABT) Xience stent in patients with ischemic heart disease. The trial is designed to evaluate the effectiveness of OrbusNeich’s combined endothelial progenitor cell capture and drug-eluting stent. The data showed that the device is non-inferior to Abbott’s drug-eluting […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Vascular, Wall Street Beat Tagged With: abbott, OrbusNeich

OrbusNeich launches Combo Plus stent

November 21, 2016 By Sarah Faulkner

OrbusNeich

OrbusNeich said today that it launched the latest version of its dual-therapy stent, the Combo Plus, featuring an antibody biological coating designed to promote vessel healing in patients with complex coronary artery disease. After the stent is implanted, the biological coating captures endothelial progenitor cells and kicks off formation of an endothelial layer. A coating of bioabsorbable polymer […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Vascular Tagged With: OrbusNeich

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS